SCHEMBL711355

SCHEMBL711355

O=C(O)Cc1ccccc1SCl

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2C9 P11712 1/20 0.56
HPGD P15428 1/20 0.56
CYP2C19 P33261 1/20 0.56
AKR1B1 P15121 3/20 0.55
TDP1 Q9NUW8 1/20 0.53
MMP2 P08253 1/20 0.48
MMP9 P14780 1/20 0.48
MMP12 P39900 1/20 0.48
CXCL8 P10145 5/20 0.47
PTGS2 P35354 2/20 0.47
TTR P02766 2/20 0.47
AKR1B10 O60218 1/20 0.47
UGT1A9 O60656 1/20 0.47
TRPA1 O75762 1/20 0.47
ABCB11 O95342 1/20 0.47
MT-CO2 P00403 1/20 0.47
ALB P02768 1/20 0.47
UGT1A6 P19224 1/20 0.47
UGT1A1 P22309 1/20 0.47
PTGS1 P23219 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4828911 0.83 AKR1B1 (0.59) CYP2C9HPGDCYP2C19AKR1B1TDP1
SCHEMBL4438683 0.83 CYP2C9 (0.69) CYP2C9HPGDCYP2C19AKR1B1TDP1
SCHEMBL28549256 0.82 L3MBTL1 (0.45) CYP2C9HPGDCYP2C19AKR1B1TDP1
SCHEMBL1146046 0.80 CYP2C9 (0.56) CYP2C9HPGDCYP2C19AKR1B1TDP1
SCHEMBL4832670 0.80 CYP2C9 (0.56) CYP2C9HPGDCYP2C19AKR1B1TDP1
SCHEMBL10555003 0.80 CYP2C9 (0.56) CYP2C9HPGDCYP2C19AKR1B1TDP1
SCHEMBL8573806 0.79 AKR1B1 (0.64) CYP2C9HPGDCYP2C19AKR1B1TDP1
SCHEMBL10424596 0.78 CYP1A2 (0.59) CYP2C9HPGDCYP2C19AKR1B1TDP1
SCHEMBL3765157 0.78 HPGD (0.78) CYP2C9HPGDCYP2C19AKR1B1TDP1
SCHEMBL29410826 0.78 AKR1B1 (0.76) CYP2C9HPGDCYP2C19AKR1B1TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8124647-B2 Non-steroidal androgens compounds N.V. ORGANON (NL) 2012-02-28 US disclosed
US-20110065768-A1 NON-STEROIDAL ANDROGENS COMPOUNDS MERCK SHARP & DOHME B.V. (NL) 2011-03-17 US disclosed
US-7795280-B2 Indoles useful in the treatment of androgen-receptor related diseases N.V. ORGANON (NL) 2010-09-14 US disclosed
EP-1585727-B1 INDOLES USEFUL IN THE TREATMENT OF ANDROGEN-RECEPTOR RELATED DISEASES ORGANON NV (NL) 2010-05-26 EP disclosed
US-20060128722-A1 Indoles useful in the treatment of androgen-receptor related diseases AKZO NOBEL N.V. (NL) 2006-06-15 US disclosed
EP-1585727-A1 INDOLES USEFUL IN THE TREATMENT OF ANDROGEN-RECEPTOR RELATED DISEASES Akzo Nobel N.V. (NL) 2005-10-19 EP disclosed
WO-2004041782-A1 INDOLES USEFUL IN THE TREATMENT OF ANDROGEN-RECEPTOR RELATED DISEASES AKZO NOBEL N.V. (NL) 2004-05-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110065768-A1 NON-STEROIDAL ANDROGENS COMPOUNDS AR, NR5A1, SHBG CYP2C9 1322/4885HPGD 1079/4885CYP2C19 1049/4885
US-20060128722-A1 Indoles useful in the treatment of androgen-receptor related diseases AR, NR5A1, SHBG CYP2C9 2137/4885HPGD 606/4885CYP2C19 1305/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.